Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors (ReRT)

The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which uses high-energy waves to kill tumor cells. In some cases, the cancer either returns or a new tumor can present in a different part of the body. With the usual radiation treatment, the photon beams travel all the way through the body. As a result, healthy tissues in front of and behind the tumor are exposed to radiation. Physicians who treat these cases where the tumor has returned often use a much lower dose of radiation to prevent patients from experiencing serious and long-term side-effects. This dose is often not strong enough to destroy the cancerous tumor. Alternatively, they may also treat a smaller area than would be indicated for complete tumor eradication, again in an attempt to prevent serious and long-term toxicities, but at the cost of optimally treating the cancer. Proton therapy, however, may offer a chance to safely deliver a more effective dose and volume of radiation as it is more targeted and can spare healthy tissues surrounding the tumor.

The reason we are conducting this research study is to look at whether Proton therapy can be a better way to treat reoccurring tumors in patients who have previously received radiation therapy to the same area, compared to treatment approaches used to date.

Study Overview

• Status: Recruiting
• Conditions: Breast Cancer; Head and Neck Cancer; Gynecologic Cancer; Prostate Cancer; Thoracic Cancer; CNS Cancer; GI Cancer
• Intervention / Treatment: Radiation: Pencil Beam Scanning Proton Therapy

• Study Type: Interventional
• Enrollment (Estimated): 1800
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ryan Holder, BS; Phone Number: 387 646-968-9055; Email: research@nyproton.com

Study Locations

• United States
  • New York
    • New York, New York, United States, 10035
      • Recruiting
      • The New York Proton Center
      • Contact: Isabelle Choi, MD; Phone Number: 646-968-9060; Email: research@nyproton.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 18 years
• Patient provides study specific informed consent prior to study entry.
• Documented history and physical exam within 90 days prior to registration.
• ECOG PS 0, 1, or 2 within 90 days prior to registration

Exclusion Criteria:

• Non malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.

• Prior invasive non study malignancy unless disease free for ≥ 3 years

  • Non melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the patient are permissible.
• History of active connective tissue disorder (i.e., systemic lupus erythematosus, scleroderma), dermatomyositis, xeroderma pigmentosum

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1: Central Nervous System; Group 1 Definitive Reirradiation Phase II; Patients w/history of intracranial or spinal (extradural, intradural, and/or intramedullary) CNS tumors for which radiation therapy was prev. delivered either to gross disease or in the postoperative setting; Min. 6 month interval b/w RT courses; Overlap of prior RT field (50% IDL); Subgroup analysis: receipt of surgery for recurrence/second IC tumor; concurrent ST; tumor histology Group 2 CNS Reirradiation Registry; Patients for whom a repeat course of RT to the CNS is indicated for recurrent disease or secondary primary; Postop or intact setting; Min. 6 month interval b/w RT courses; Overlap of prior RT field (50% IDL); Histologically/clinically documented recurrent CNS tumor (benign or malignant); Glioblastoma (histologic or molecular including IDH wildtype); Astrocytoma (molecular IDH1 mutant); Oligodendroglioma (molecular 1p19q co deleted); Meningioma; Ependymoma; Chordoma/chondrosarcoma	Radiation: Pencil Beam Scanning Proton Therapy; Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
Experimental: Cohort 2: Head/Neck; Group 1 Full Dose Reirradiation Phase II; Patients w/history of HNC for which RT was delivered definitively, now with recurrence to h/n amenable to full dose reRT; Gross unresected disease or PORT 2/2 RF; Received at least 40 Gy overlapping w/new target region; Min. 6 month interval b/w RT courses; Overlap of prior RT field (50% IDL); Subgroup analysis: surgery, HPV status, concurrent ST Group 2 Early (<6months for prior RT) Palliative H/N ReRT Phase I; Patients w/history of HNC for which RT was delivered definitively/adjuvant setting, now with biopsy proven recurrence to h/n with indication for palliative RT; At least 30 Gy prior RT overlapping with new treatment volume; <6 month interval between RT courses Group 3 Head/Neck ReRT Registry; Patients w/history of HNC for which RT was delivered now with recurrence/secondary primary requiring reRT; Postop or definitive; Prior RT dose at least 30 Gy overlapping w/new treatment volume; Min.6 month interval b/w RT courses	Radiation: Pencil Beam Scanning Proton Therapy; Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
Experimental: Cohort 3: Breast; Group 1 Partial Breast Reirradiation (Phase II); Patients with a history of breast cancer s/p BCT, now with small (≤3cm), unicentric, ipsilateral breast cancer recurrence receiving repeat BCT; Node negative; Negative margins; No LVI; Lumpectomy cavity:whole breast <30%; Minimum 1 year interval between RT courses Group 2: Regional LN and Breast/CW ReRT (Phase II); Patients with a history of breast cancer s/p RT , now with recurrence or new primary with indication for reirradiation to the breast/chest wall and regional LN; Minimum 1 year interval between RT courses; Negative metastatic workup (PET/CT or CT C/A/P + bone scan); Excludes concurrent chemotherapy Group 3: Breast Reirradiation Registry; Patients with a history of breast cancer s/p RT , now with recurrence or new primary breast cancer with indication for reirradiation; Some overlaps of dose with prior RT course; Negative metastatic workup (PET/CT or CT C/A/P + bone scan); Excludes concurrent chemotherapy	Radiation: Pencil Beam Scanning Proton Therapy; Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
Experimental: Cohort 4: Thoracic; Group 1: Definitive Reirradiation for Locally Advanced Disease; Single arm, prospective, phase II study; Patients with a history of lung cancer s/p definitive RT , now with local recurrence of new primary centrally located and w/I 50% IDL of prior RT field; Definitive reRT concurrent systemic therapy; Adequate pulmonary function defined as an FEV1 of >35% (with or without bronchodilator) within 90 days prior to registration; Minimum 6 month interval between RT courses; Negative metastatic workup Group 2: Thoracic Registry Study; Registry design; Patients with histologically confirmed thoracic malignancy (NSCLC, SCLC , mesothelioma, thymoma, carcinoid, intrathoracic sarcoma) with prior thoracic RT; Minimum 3 month interval between RT courses; Negative metastatic workup	Radiation: Pencil Beam Scanning Proton Therapy; Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
Experimental: Cohort 5: Gastrointestinal; Group 1 Esophagus & GEJ Reirradiation Phase II; Patients w/history of E/GEJ cancer s/p RT, now w/recurrent/new primary nonmetastatic E/GEJ cancer for which salvage RT is recommended; Negative metastatic workup Group 2 Liver Reirradiation Phase II; Patients w/history of HCC, cholangiocarcinoma or liver mets (any histology), s/p prior EBRT, now with in field recurrence/new primary/met, for which definitive reRT is recommended; CTP A or B7; Excl. prev. Y 90/radioembolization; Allow prior TACE; Overlap w/50% IDL prior RT; Adequate bone marrow function Group 3 Lower GI Reirradiation Phase II; Patients w/history of rectal/anal cancer s/p RT now w/recurrent/new primary nonmetastatic rectal/anal cancer for whom salvage RT is recommended +/ chemotherapy; Negative metastatic workup (PET/CT or CT C/A/P) Group 4 GI Reirradiation Registry •Patients w/histologically document recurrent or new GI malignancy with prior history of RT w/overlap of current RT volume by the 50% IDL	Radiation: Pencil Beam Scanning Proton Therapy; Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
Experimental: Cohort 6: Genitourinary; Group 1 Locally recurrent prostate cancer w/in prev. radiation field Phase II; Patients w/recurrent prostate adenocarcinoma w/in prev. irradiated field w/indication for repeat course of radiation; Min. 1 year interval b/w RT courses; Prostate gland or recurrent tumor <100 cc or 6 cm in largest dimension; No persistent grade 2+ toxicity from prior radiation; Negative metastatic workup (bone scan, CT scan or PSMA/axumin scan Group 2 Regional prostate cancer recurrence adjacent to the previous field Phase II; Patients w/recurrent prostate adenocarcinoma beyond prior RT field (outside 50% IDL) but w/in pelvis); Min.1 year interval b/w RT courses (EBRT or brachy); No persistent grade 2+ toxicity from prior radiation Group 3 Prostate Reirradiation Registry; Patients w/recurrent prostate adenocarcinoma (prostate gland, postop bed, or pelvi c LN) who require RT to the prostate or pelvis in the setting of prior pelvis RT; No DM; Concurrent chemotherapy excl.	Radiation: Pencil Beam Scanning Proton Therapy; Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
Experimental: Cohort 7: Gynecological; Group 1: Locally recurrent gynecological cancer within previous field; Single arm, prospective, phase II study design; Patients with history of gyn cancer for which definitive or adjuvant/salvage PORT was given, now with recurrence within 50% IDL recommended for radiotherapy; At least 1 year between RT courses; No persistent grade 3+ toxicity from prior RT; Concurrent chemotherapy excluded; Uncontrolled or widely metastatic disease; Life expectancy >6 months	Radiation: Pencil Beam Scanning Proton Therapy; Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
No Intervention: Cohort 8: Registry; Registry design; Any cancer patient for whom RT is indicated in the setting of prior RT and do not meet eligibility criteria for other cohorts; Overlap of 50% IDL of current treatment volume with prior RT field

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To determine the cumulative rate of CTCAE v5.0 Grade ≥3 acute and late treatment related adverse events within 1 year of definitive reirradiation completion using proton therapy for recurrent or second primary tumor.	5 years

Secondary Outcome Measures

Outcome Measure	Time Frame
To determine the 1 year freedom from local failure.	1 year
To determine the 1 year freedom from progression free survival.	1 year
To determine the 1 year freedom from overall survival.	1 year
To determine the acute cumulative rate of CTCAE v5.0 Grade ≥3 treatment related adverse events at 90 days of reirradiation completion.	90 days
To determine the late cumulative rate of CTCAE v5.0 Grade ≥3 treatment related adverse events at 2 years of reirradiation completion.	2 years
To characterize patient reported outcomes within 1 year of reirradiation using the MDASI BT forms for intracranial tumors.	1 years
To characterize patient reported outcomes within 1 year of reirradiation using the CTB COMP forms for intracranial tumors.	1 years
To characterize patient reported outcomes within 1 year of reirradiation using the MDASI SP form for spinal tumors.	1 year

Collaborators and Investigators

• Sponsor: The New York Proton Center

Study record dates

Study Major Dates

• Study Start (Actual): January 24, 2022
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2028

Study Registration Dates

• First Submitted: March 21, 2022
• First Submitted That Met QC Criteria: March 29, 2022
• First Posted (Actual): April 6, 2022

Study Record Updates

• Last Update Posted (Actual): April 13, 2026
• Last Update Submitted That Met QC Criteria: April 6, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Cancer; Radiation Therapy; Proton Therapy; Reirradiation
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Nervous System Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Skin Diseases; Breast Diseases; Nervous System Neoplasms; Skin and Connective Tissue Diseases; Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Central Nervous System Neoplasms
• Other Study ID Numbers: NYPC ERC# 2019-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No